GSK, Indirect Purchasers Plan To Settle Pay-For-Delay Suit
The parties in a lawsuit challenging a pay-for-delay settlement between Teva Pharmaceuticals and GlaxoSmithKline over the latter's epilepsy drug Lamictal are planning to settle the complaint, according to a letter filed...To view the full article, register now.
Already a subscriber? Click here to view full article